ARGX vs BNTX: stock comparison and AI forecast
Argenx Se (ARGX) and Biontech Se (BNTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ARGX Argenx Se
- Price
- $894.77 +13.6% · 6M
- Market Cap
- $55.37B
- P/E Ratio
- 23.5x
- Size
- large-cap
- AI Forecast
BNTX Biontech Se
- Market Cap
- $21.71B
- P/E Ratio
- 2.2x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ARGX is 2.6 times larger than BNTX by market capitalization ($55.37B against $21.71B).
- BNTX trades at 2.2 times trailing earnings, ARGX at 23.5 times.
- ARGX carries 0.19 times debt per unit of equity, against 0.14 times for BNTX.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ARGX | BNTX |
|---|---|---|
| Market Cap | $55.37B | $21.71B |
| P/E Ratio | 23.47x | 2.22x |
| EPS | $38.12 | $38.67 |
| Revenue/Share | – | $119.85 |
| FCF/Share | $13.34 | $83.21 |
Profitability & Margins
| Metric | ARGX | BNTX |
|---|---|---|
| ROE | 34.2% | 44.5% |
| ROA | 28.9% | 38.9% |
| ROIC | 16.8% | 53.5% |
| Gross Margin | – | 82.1% |
| Operating Margin | – | 39.7% |
| Net Margin | – | 32.0% |
| EBT Margin | – | 46.4% |
| Tax Rate | -42.2% | 31.0% |
Financial Health
| Metric | ARGX | BNTX |
|---|---|---|
| Current Ratio | 5.23x | 7.54x |
| Quick Ratio | 4.87x | 7.49x |
| D/E Ratio | 0.19x | 0.14x |
| Financial Leverage | 1.19x | 1.14x |
| Working Capital | $5.58B | $16.45B |
Cash Flow
| Metric | ARGX | BNTX |
|---|---|---|
| Operating Cash Flow | $840M | $22.22B |
| Free Cash Flow | $826M | $21.04B |
| Capital Spending | -$14M | -$1.18B |
| FCF Growth YoY | 0.0% | 0.0% |
| FCF/Sales | – | 69.4% |
| CapEx/Sales | – | 3.9% |
Operational Efficiency
| Metric | ARGX | BNTX |
|---|---|---|
| Asset Turnover | – | 1.22x |
| Receivables Turnover | – | 28.9x |
| Inventory Turnover | 2.0x | 43.2x |
| Fixed Assets Turnover | – | 24.8x |
| Days Sales Outstanding | – | 13 days |
| Days Inventory | 179 days | 8 days |
| Payables Period | 479 days | 41 days |
| Cash Conversion Cycle | – | -20 days |
Income Statement
| Metric | ARGX | BNTX |
|---|---|---|
| Total Revenue | – | $30.31B |
| Operating Income | $1.23B | $12.03B |
| Net Income | $2.51B | $9.70B |
| R&D Expense | $3.43B | $8.70B |
| SG&A Expense | $3.52B | – |
| Cost of Goods Sold | $965M | $5.41B |
Dividend & Shareholder Information
| Metric | ARGX | BNTX |
|---|---|---|
| Shares Outstanding | 62M | 253M |
ARGX vs BNTX: stock comparison and AI forecast
Which is bigger, ARGX or BNTX?
ARGX is 2.6 times larger than BNTX by market capitalization ($55.37B against $21.71B).
Which is cheaper on earnings, ARGX or BNTX?
BNTX trades at 2.2 times trailing earnings, ARGX at 23.5 times.
Which one does Intratio's AI model rank higher, ARGX or BNTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.